Steven R. Goldring
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Steven R. Goldring has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Ellen M. Gravallese
Harvard Institutes of Medicine
2 shared publications
Latest Publications
- 1 August 2003
- Published by Springer Nature in Calcified Tissue International
- Vol. 73 (2) , 97-100
Inflammatory Mediators as Essential Elements in Bone Remodeling
Inflammatory disorders such as rheumatoid arthritis (RA), may have profound effects on skeletal homeostasis. In contrast to physiologic remodeling in which mechanical influences and/or systemic endocrine hormones initiate the remodeling process, in disorders such as RA the recruitment of macrophage lineage cells to sites of inflammation and the action of local osteoclastogenic cytokines associated with the inflammatory process initiate the remodeling process. In both physiologic and pathologic remodeling, osteoclasts appear to be the principal cell type responsible for the bone resorption. In addition, many of the same cytokines and mediators are involved in physiologic and pathologic bone remodeling. These observations have important implications with respect to the development of therapeutic strategies to prevent bone loss in inflammatory conditions.
- 1 August 2003
- Published by Springer Nature in Calcified Tissue International
- Vol. 73 (2) , 97-100
Inflammatory Mediators as Essential Elements in Bone Remodeling
Inflammatory disorders such as rheumatoid arthritis (RA), may have profound effects on skeletal homeostasis. In contrast to physiologic remodeling in which mechanical influences and/or systemic endocrine hormones initiate the remodeling process, in disorders such as RA the recruitment of macrophage lineage cells to sites of inflammation and the action of local osteoclastogenic cytokines associated with the inflammatory process initiate the remodeling process. In both physiologic and pathologic remodeling, osteoclasts appear to be the principal cell type responsible for the bone resorption. In addition, many of the same cytokines and mediators are involved in physiologic and pathologic bone remodeling. These observations have important implications with respect to the development of therapeutic strategies to prevent bone loss in inflammatory conditions.
- Open Access
- 1 May 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (90002) , 11ii-16
Pathogenesis of bone and cartilage destruction in rheumatoid arthritis
Proinflammatory cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor alpha (TNFα), have been implicated in the dysregulation of bone and cartilage remodelling characteristic of rheumatoid arthritis (RA). With respect to bone remodelling, both of these cytokines have been shown to up-regulate the production of the receptor activator of nuclear factor-κB ligand, which acts to enhance osteoclastic bone resorption. TNFα stimulates differentiation of osteoclast progenitors into mature osteoclasts and IL-1 acts directly on osteoclasts to increase the bone-resorbing capacity of these cells. IL-1 and TNFα also adversely affect cartilage remodelling, although IL-1 is more potent on a molar basis. This cytokine not only increases production of factors that stimulate cartilage matrix degradation, but also inhibits the synthesis of type II collagen and proteoglycans. Enhanced understanding of the mechanisms underlying the processes of joint destruction will allow more selective and specific application of therapeutic agents that target these pro-inflammatory cytokines and, thus, more effective management of patients with RA and other inflammatory disorders.
- 1 May 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (90002) , 11ii-16
Open AccessPathogenesis of bone and cartilage destruction in rheumatoid arthritis
Proinflammatory cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor alpha (TNFα), have been implicated in the dysregulation of bone and cartilage remodelling characteristic of rheumatoid arthritis (RA). With respect to bone remodelling, both of these cytokines have been shown to up-regulate the production of the receptor activator of nuclear factor-κB ligand, which acts to enhance osteoclastic bone resorption. TNFα stimulates differentiation of osteoclast progenitors into mature osteoclasts and IL-1 acts directly on osteoclasts to increase the bone-resorbing capacity of these cells. IL-1 and TNFα also adversely affect cartilage remodelling, although IL-1 is more potent on a molar basis. This cytokine not only increases production of factors that stimulate cartilage matrix degradation, but also inhibits the synthesis of type II collagen and proteoglycans. Enhanced understanding of the mechanisms underlying the processes of joint destruction will allow more selective and specific application of therapeutic agents that target these pro-inflammatory cytokines and, thus, more effective management of patients with RA and other inflammatory disorders.
- 1 September 2002
- Vol. 65, 44-8
Bone and joint destruction in rheumatoid arthritis: what is really happening?
Focal bone erosions occur at the joint margins and in subchondral bone of patients with rheumatoid arthritis (RA). These erosions progress throughout the course of disease and generally correlate with disease severity. Tissue sections from sites of bone erosion in the rheumatoid joint show multinucleated cells with phenotypic characteristics of osteoclasts, the cells responsible for resorbing bone during physiologic remodeling. Factors known to directly or indirectly induce osteoclast differentiation and activation are found in the rheumatoid synovium. These include receptor activator of NF-kappaB ligand (RANKL), which plays a critical role in osteoclast differentiation, as well as a variety of proinflammatory cytokines, including intereukin 1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha), which upregulate RANKL. IL-1 also augments osteoclast activation, and TNF-alpha induces differentiation of early osteoclast precursors. In animal models of RA, RANKL is expressed at sites of bone erosion. Moreover, in a serum transfer model of inflammatory arthritis, animals unable to produce osteoclasts did not show evidence of bone resorption despite the presence of intense inflammation. These observations suggest that osteoclasts mediate focal bone erosions in RA and that targeting of osteoclasts and osteoclast mediated bone resorption represents a rational approach to preventing or reducing focal bone loss in RA.
- 1 September 2002
- Vol. 65, 44-8
Bone and joint destruction in rheumatoid arthritis: what is really happening?
Focal bone erosions occur at the joint margins and in subchondral bone of patients with rheumatoid arthritis (RA). These erosions progress throughout the course of disease and generally correlate with disease severity. Tissue sections from sites of bone erosion in the rheumatoid joint show multinucleated cells with phenotypic characteristics of osteoclasts, the cells responsible for resorbing bone during physiologic remodeling. Factors known to directly or indirectly induce osteoclast differentiation and activation are found in the rheumatoid synovium. These include receptor activator of NF-kappaB ligand (RANKL), which plays a critical role in osteoclast differentiation, as well as a variety of proinflammatory cytokines, including intereukin 1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha), which upregulate RANKL. IL-1 also augments osteoclast activation, and TNF-alpha induces differentiation of early osteoclast precursors. In animal models of RA, RANKL is expressed at sites of bone erosion. Moreover, in a serum transfer model of inflammatory arthritis, animals unable to produce osteoclasts did not show evidence of bone resorption despite the presence of intense inflammation. These observations suggest that osteoclasts mediate focal bone erosions in RA and that targeting of osteoclasts and osteoclast mediated bone resorption represents a rational approach to preventing or reducing focal bone loss in RA.
- 1 July 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (4) , 406-410
Pathogenesis of bone erosions in rheumatoid arthritis
Focal marginal joint erosions represent the radiographic hallmark of rheumatoid arthritis (RA). These bone changes are characteristically localized to the joint margins, but in addition, regions of focal bone resorption can be detected in the subchondral bone adjacent to the bone marrow space into which the synovial inflammatory tissues have extended. Because progressive destruction of the periarticular bone contributes significantly to joint dysfunction and disability in patients with RA, there is considerable interest in developing a better understanding of the pathologic mechanisms involved in this process and in developing therapies that can arrest these events. Previous analysis of joint tissues from patients with RA have provided morphologic evidence that osteoclasts are the cell types that mediate the focal bone resorption associated with the rheumatoid synovial lesion. Additional recent data from animal models have helped to further implicate these cells in the pathogenesis of focal bone erosions. Furthermore, analysis of RA synovium and joint tissues from animal models of inflammatory arthritis, as well as cell and tissues culture studies, have helped to define the cytokines and inflammatory mediators that are involved in the recruitment and activation of bone resorbing cells associated with focal bone erosions. These findings provide a rational framework for developing targeted therapies that can specifically inhibit or slow the progressive focal bone destruction associated with the rheumatoid synovial lesion.
- 1 July 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (4) , 406-410
Pathogenesis of bone erosions in rheumatoid arthritis
Focal marginal joint erosions represent the radiographic hallmark of rheumatoid arthritis (RA). These bone changes are characteristically localized to the joint margins, but in addition, regions of focal bone resorption can be detected in the subchondral bone adjacent to the bone marrow space into which the synovial inflammatory tissues have extended. Because progressive destruction of the periarticular bone contributes significantly to joint dysfunction and disability in patients with RA, there is considerable interest in developing a better understanding of the pathologic mechanisms involved in this process and in developing therapies that can arrest these events. Previous analysis of joint tissues from patients with RA have provided morphologic evidence that osteoclasts are the cell types that mediate the focal bone resorption associated with the rheumatoid synovial lesion. Additional recent data from animal models have helped to further implicate these cells in the pathogenesis of focal bone erosions. Furthermore, analysis of RA synovium and joint tissues from animal models of inflammatory arthritis, as well as cell and tissues culture studies, have helped to define the cytokines and inflammatory mediators that are involved in the recruitment and activation of bone resorbing cells associated with focal bone erosions. These findings provide a rational framework for developing targeted therapies that can specifically inhibit or slow the progressive focal bone destruction associated with the rheumatoid synovial lesion.
- 1 May 2002
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 4 (3) , 226-231
Pathogenesis of bone lesions in rheumatoid arthritis
Histopathologic characterization of bone erosions from patients with rheumatoid arthritis (RA) and studies performed in animal models of inflammatory arthritis provide strong evidence that osteoclasts play an important role in focal marginal and subchondral bone loss in inflammatory arthritis. Much has been learned concerning the factors responsible for the induction and activation of osteoclasts associated with the bone erosions in RA. Therapies that target these osteoclast-inducing factors or other aspects of osteoclast-mediated bone resorption represent potential targets for blocking or at least attenuating bone destruction in RA. The demonstration of the role of the newly described osteoclastogenic factor receptor activator of nuclear factor kappaB ligand in RA synovial tissues and the successful prevention of bone erosions in animal models of arthritis with its inhibitor osteoprotegerin provide hope that specific therapies can be developed for preventing bone and joint destruction in RA, particularly in situations in which disease-modifying agents are ineffective in controlling disease activity.
- 1 May 2002
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 4 (3) , 226-231
Pathogenesis of bone lesions in rheumatoid arthritis
Histopathologic characterization of bone erosions from patients with rheumatoid arthritis (RA) and studies performed in animal models of inflammatory arthritis provide strong evidence that osteoclasts play an important role in focal marginal and subchondral bone loss in inflammatory arthritis. Much has been learned concerning the factors responsible for the induction and activation of osteoclasts associated with the bone erosions in RA. Therapies that target these osteoclast-inducing factors or other aspects of osteoclast-mediated bone resorption represent potential targets for blocking or at least attenuating bone destruction in RA. The demonstration of the role of the newly described osteoclastogenic factor receptor activator of nuclear factor kappaB ligand in RA synovial tissues and the successful prevention of bone erosions in animal models of arthritis with its inhibitor osteoprotegerin provide hope that specific therapies can be developed for preventing bone and joint destruction in RA, particularly in situations in which disease-modifying agents are ineffective in controlling disease activity.
- Open Access
- 1 November 2000
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 59 (suppl 1) , i72-i74
The final pathogenetic steps in focal bone erosions in rheumatoid arthritis
- 1 November 2000
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 59 (suppl 1) , i72-i74
Open AccessThe final pathogenetic steps in focal bone erosions in rheumatoid arthritis
- 1 May 2000
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 12 (3) , 195-199
Pathogenesis of bone erosions in rheumatoid arthritis
Patients with rheumatoid arthritis are at risk for the development of a generalized form of bone loss affecting the axial and appendicular skeleton. In addition, juxta-articular osteopenia and focal erosion of marginal and subchondral bone are commonly seen. The pathogenesis of focal bone erosions is an area of active investigation. Studies of tissue sections from sites of bone erosion in rheumatoid arthritis and in animal models of inflammatory arthritis have identified multinucleated cells with the phenotype of osteoclasts in bone resorption lacunae in these sites, suggesting that osteoclasts mediate a component of this pathologic bone loss. Numerous soluble and cell-membrane factors produced by rheumatoid synovial tissues are likely to play a role in the initiation and progression of bone erosions. In addition, recent studies suggest a role for T lymphocytes and their products in osteoclast-mediated bone loss. This paper reviews the cellular mechanisms and factors implicated in bone erosions in rheumatoid arthritis, and discusses the possible therapeutic strategies suggested by these findings.
- 1 May 2000
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 12 (3) , 195-199
Pathogenesis of bone erosions in rheumatoid arthritis
Patients with rheumatoid arthritis are at risk for the development of a generalized form of bone loss affecting the axial and appendicular skeleton. In addition, juxta-articular osteopenia and focal erosion of marginal and subchondral bone are commonly seen. The pathogenesis of focal bone erosions is an area of active investigation. Studies of tissue sections from sites of bone erosion in rheumatoid arthritis and in animal models of inflammatory arthritis have identified multinucleated cells with the phenotype of osteoclasts in bone resorption lacunae in these sites, suggesting that osteoclasts mediate a component of this pathologic bone loss. Numerous soluble and cell-membrane factors produced by rheumatoid synovial tissues are likely to play a role in the initiation and progression of bone erosions. In addition, recent studies suggest a role for T lymphocytes and their products in osteoclast-mediated bone loss. This paper reviews the cellular mechanisms and factors implicated in bone erosions in rheumatoid arthritis, and discusses the possible therapeutic strategies suggested by these findings.